(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(dodecoxymethyl)oxane-3,4,5-triol | 13047-15-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(dodecoxymethyl)oxane-3,4,5-triol
• CAS: 13047-15-9
• 化学式: C₂₄H₄₆O₁₁
• 分子量: 510.623
• InChiKey: GXEYNMVVRBLPNP-IUYXUTJNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  35
• 可旋转键数：
  17
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  179
• 氢给体数：
  7
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  溴代十二烷 、 蔗糖 在 吡啶 、 三苯基氯甲烷 、 四丁基溴化铵 、 溴甲苯 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(dodecoxymethyl)oxane-3,4,5-triol 、 (2R,3R,4S,5S,6R)-2-(((2S,3S,4S,5R)-5-((dodecyloxy)methyl)-3,4-dihydroxy-2-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
  参考文献：
  名称：

  Self-Assembling Properties of 6-O- and 6′-O-Alkylsucrose Mixtures Having Different Chain Lengths Under Aqueous Conditions

  摘要：

  The self-assembling properties of the 6-O- and 6-O-alkylsucrose mixtures with different chain lengths including octyl, decyl, dodecyl, and tetradecyl under aqueous conditions were studied and compared with those of the 6-O- and 6-O-hexadecylsucrose mixture previously reported. The title compounds were synthesized from sucrose in five steps. The results of scanning and transmission electron microscopes, powder X-ray diffraction, and dynamic light scattering measurements indicated that the self-assembling properties of octyl, decyl, and dodecyl derivatives were completely different from those of the 6-O- and 6-O-hexadecylsucrose mixture. The three derivatives reported here primarily formed lamellar planes, which further induced the formation of vesicle-type particles under aqueous conditions, whereas the previous derivatives primarily formed spherical micelles in water, which further assembled according to face-centered cubic organization by a drying process from the aqueous dispersion. It was also found that the 6-O- and 6-O-tetradecylsucrose mixture showed concentration-induced micelle-lamellar transition behavior in an aqueous dispersion. Furthermore, the mixing of a regioisomer, 6-O-hexadecylsucrose, with 6-O-hexadecylsucrose induced different self-assembling properties from that of 6-O-hexadecylsucrose alone, but this effect did not appear in the self-assembling of the 6-O- and 6-O-octylsucrose mixture.

  DOI：

  10.1080/07328303.2013.809094

文献信息

• Acylated Exendin-4 Compounds
  申请人：Lau Jesper

  公开号：US20090318353A1

  公开（公告）日：2009-12-24

  This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such.

  本发明提供了新的治疗性肽，即新的长效Exendin-4化合物、药物组合物及其用途。
• Long-Acting Y2 and/or Y4 Receptor Agonists
  申请人：Østergaard Søren

  公开号：US20110275559A1

  公开（公告）日：2011-11-10

  The present invention relates to a PYY or PP peptide derivative or analogue thereof derivatised with one or more serum albumin binding side chains comprising a dis-tal tetrazole or carboxylic acid group. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y receptor modulation.

  本发明涉及一种与一种或多种血清白蛋白结合侧链衍生物或类似物衍生物化合的PYY或PP肽衍生物，其中包括一个远端四唑基或羧酸基团。此外，本发明涉及这些组合物以及对于对Y受体调节敏感的病况的治疗方法。
• NICOTINAMIDE RIBOSIDE DERIVATIVES AND THEIR USES
  申请人：GANAPATI Gangadhara

  公开号：US20180362570A1

  公开（公告）日：2018-12-20

  The disclosure provides derivatives of both the oxidized form and the reduced form of nicotinamide riboside (NR) and nicotinic acid riboside (NAR). The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR, and can increase cellular NAD + levels and improve mitochondrial function. Therefore, the NR and NAR derivatives are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, and other disorders and conditions.

  该披露提供了烟酰胺核苷酸（NR）和烟酸核苷酸（NAR）的氧化形式和还原形式的衍生物。与NR和NAR相比，NR和NAR衍生物具有更好的稳定性和生物利用度，并且可以增加细胞NAD+水平并改善线粒体功能。因此，NR和NAR衍生物对治疗线粒体疾病、与线粒体相关的疾病和症状以及其他疾病和症状具有用处。
• NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES
  申请人：MitoPower, LLC

  公开号：US20200397807A1

  公开（公告）日：2020-12-24

  The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR. NR, NRH, NAR, NARH, and derivatives thereof can increase cellular NAD + levels and enhance mitochondrial and cellular function and cell viability. Therefore, NR, NRH, NAR, NARH, and derivatives thereof, whether alone or in combination with one or more additional therapeutic agents (e.g., a mitochondrial uncoupler or/and a PARP inhibitor), are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, metabolic disorders, and other disorders and conditions.

  该披露提供烟酰胺核糖苷（NR）、烟酰胺核糖苷的还原形式（NRH）、烟酸核糖苷（NAR）、烟酸核糖苷的还原形式（NARH）、以及它们的衍生物、组合物和用途。与NR和NAR相比，NR和NAR的衍生物具有更好的稳定性和生物利用度。NR、NRH、NAR、NARH和它们的衍生物可以增加细胞NAD+水平，增强线粒体和细胞功能以及细胞存活能力。因此，NR、NRH、NAR、NARH和它们的衍生物，无论是单独使用还是与一个或多个额外治疗剂（例如线粒体解耦蛋白抑制剂和/或PARP抑制剂）结合使用，都可用于治疗线粒体疾病、与线粒体相关的疾病和症状、代谢紊乱以及其他疾病和症状。
• Compositions for Nasal Administration of Phenothiazines
  申请人：GUY David

  公开号：US20100215730A1

  公开（公告）日：2010-08-26

  Provided herein are pharmaceutical compositions comprising phenothiazines or derivatives thereof that are formulated for nasal administration. Also provided herein are methods of utilizing the same.

  本文提供了一种含有苯并噻唑或其衍生物的药物组合物，该药物组合物适用于鼻腔给药。本文还提供了使用该药物组合物的方法。